Suppr超能文献

无症状动脉粥样硬化疾病可视化以实现最佳心血管预防(VIPVIZA):一项实用、开放标签、随机对照试验。

Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.

机构信息

Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Unit of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

出版信息

Lancet. 2019 Jan 12;393(10167):133-142. doi: 10.1016/S0140-6736(18)32818-6. Epub 2018 Dec 3.

Abstract

BACKGROUND

Primary prevention of cardiovascular disease often fails because of poor adherence among practitioners and individuals to prevention guidelines. We aimed to investigate whether ultrasound-based pictorial information about subclinical carotid atherosclerosis, targeting both primary care physicians and individuals, improves prevention.

METHODS

Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA) is a pragmatic, open-label, randomised controlled trial that was integrated within the Västerbotten Intervention Programme, an ongoing population-based cardiovascular disease prevention programme in northern Sweden. Individuals aged 40, 50, or 60 years with one or more conventional risk factors were eligible to participate. Participants underwent clinical examination, blood sampling, and ultrasound assessment of carotid intima media wall thickness and plaque formation. Participants were randomly assigned 1:1 with a computer-generated randomisation list to an intervention group (pictorial representation of carotid ultrasound plus a nurse phone call to confirm understanding) or a control group (not informed). The primary outcomes, Framingham risk score (FRS) and European systematic coronary risk evaluation (SCORE), were assessed after 1 year among participants who were followed up. This study is registered with ClinicalTrials.gov, number NCT01849575.

FINDINGS

3532 individuals were enrolled between April 29, 2013, and June 7, 2016, of which 1783 were randomly assigned to the control group and 1749 were assigned to the intervention group. 3175 participants completed the 1-year follow-up. At the 1-year follow-up, FRS and SCORE differed significantly between groups (FRS 1·07 [95% CI 0·11 to 2·03, p=0·0017] and SCORE 0·16 [0·02 to 0·30, p=0·0010]). FRS decreased from baseline to the 1-year follow-up in the intervention group and increased in the control group (-0·58 [95% CI -0·86 to -0·30] vs 0·35 [0·08 to 0·63]). SCORE increased in both groups (0·13 [95% CI 0·09 to 0·18] vs 0·27 [0·23 to 0·30]).

INTERPRETATION

This study provides evidence of the contributory role of pictorial presentation of silent atherosclerosis for prevention of cardiovascular disease. It supports further development of methods to reduce the major problem of low adherence to medication and lifestyle modification.

FUNDING

Västerbotten County Council, the Swedish Research Council, the Heart and Lung Foundation, the Swedish Society of Medicine, and Carl Bennet Ltd, Sweden.

摘要

背景

由于从业者和个体对预防指南的依从性差,心血管疾病的一级预防经常失败。我们旨在研究针对初级保健医生和个体的亚临床颈动脉粥样硬化的基于超声的图像信息是否可以改善预防效果。

方法

可视化无症状动脉粥样硬化疾病以实现最佳心血管预防(VIPVIZA)是一项实用的、开放标签的、随机对照试验,该试验整合于瑞典北部正在进行的基于人群的心血管疾病预防计划——韦斯特博滕干预计划内。年龄在 40、50 或 60 岁之间且有一个或多个传统危险因素的个体有资格参与。参与者接受了临床检查、血液采样以及颈动脉内膜中层壁厚度和斑块形成的超声评估。参与者采用计算机生成的随机分组列表,以 1:1 的比例随机分配到干预组(颈动脉超声的图像表示加上护士打电话确认理解)或对照组(不告知)。在随访的参与者中,在 1 年后评估主要结局,即弗雷明汉风险评分(FRS)和欧洲系统性冠状动脉风险评估(SCORE)。该研究在 ClinicalTrials.gov 上注册,编号为 NCT01849575。

结果

2013 年 4 月 29 日至 2016 年 6 月 7 日期间共纳入 3532 名参与者,其中 1783 名随机分配到对照组,1749 名分配到干预组。3175 名参与者完成了 1 年的随访。在 1 年的随访中,组间 FRS 和 SCORE 差异显著(FRS 为 1.07 [95%CI 0.11 至 2.03,p=0.0017],SCORE 为 0.16 [0.02 至 0.30,p=0.0010])。干预组的 FRS 从基线到 1 年随访时降低,对照组升高(-0.58 [95%CI -0.86 至 -0.30] 与 0.35 [0.08 至 0.63])。两组的 SCORE 均升高(0.13 [95%CI 0.09 至 0.18] 与 0.27 [0.23 至 0.30])。

结论

这项研究提供了无声动脉粥样硬化的图像呈现对心血管疾病预防的有益作用的证据。它支持进一步开发方法来减少药物治疗和生活方式改变依从性低这一主要问题。

资金来源

韦斯特博滕县议会、瑞典研究委员会、心脏和肺基金会、瑞典医学协会以及瑞典卡尔·贝内特有限公司。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验